Sirnaomics Ltd. · HKEX:2257
Sirnaomics — H1 2023 Earnings Presentation
44 slides from Sirnaomics's earnings presentation, 2023

Slide 1: Sirnaomics Ltd. 2023 Interim Results Presentation
Sirnaomics Ltd. (2257.HK) 2023 Interim Results Presentation 0

Slide 2: Disclaimer
Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by

Slide 3: Presenters
Presenters Patrick Lu, PhD Michael V. Molyneaux, MD, Nigel Yip, MBA Founder, Chairman of the Board, MBA Executive Director, Executive Director, CMO Chief Financial Officer President & CEO 30+ years of experience 20+ years of experience 15+ years of experience 2

Slide 4: Agenda
Agenda 01 - Company Overview 02 - Prioritized Pipeline and Delivery Platforms 03 - Clinical Achievements 04 - Future Milestones and Catalysts 05 - Financial Highlights 3

Slide 5: Company Overview
° ° Advancing RNAi Therapeutics PEAS Company Overview ele

Slide 6: Sirnaomics: International Vision in RNA therapy
Sirnaomics: International Vision in RNA therapy Dual Exclusive Delivery Accelerate Clinical Advancement Leadership in RNA for Cancer Platforms STP705 isSCC Late-stage Treatment on the Global Stage STP705 BCC Phase II (completed) PNP platform First company to achieve positive Phase II STP705 Fat Remo

Slide 7: Experienced Management Team Led by RNA Pioneer
Experienced Management Team Led by RNA Pioneer Outstanding Achievements and Awards ◼ 30+ years of nucleic acid drug development experience ◼ Serial entrepreneur: founder of Sirnaomics & cofounder of RNAimmune, Intradigm and EDIRNA ◼ A senior expert in Gene Therapy and Nucleic Acid Delivery, and an i

Slide 8: Prioritized Pipeline and Delivery Platforms
Prioritized Pipeline and Delivery Platforms 7

Slide 9: Prioritized Product Pipeline Advancing Oncology Programs
Prioritized Product Pipeline Advancing Oncology Programs Delivery Pre- IND Candidate Gene Targets Indications IND Phase I Phase II Phase III Rights Status Platform clinical Enabling Obtained guidance isSCC Global from FDA for late- stage trial STP705 TGF-β1/COX-2 PNP-IT Reached optimal Oncology BCC

Slide 10: Two Proprietary Delivery Platforms with Clinical Assets
Two Proprietary Delivery Platforms with Clinical Assets 1 Polypeptide Nanoparticle (PNP) Platform 2 GalNAc Platform Cell penetration property (CPP) siRNA GalAheadTM HKP and HKP(+H) are well suited for siRNA Therapeutics or mRNA Therapeutics and Vaccine Deliveries Liver Metabolic mRNA Cancer Fibrosis

Slide 11: Unique Property of PNP for siRNA Delivery
Unique Property of PNP for siRNA Delivery Structure Mechanism of delivery ~100 nm Inherently safe structure Unique properties for PNP Efficient endosome escape ◼ Biodegradable histidine-lysine ◼ The percentage of endosome escape branched polypeptides translates to the efficiency of delivery of ◼ Pol

Slide 12: Polypeptide Nanoparticle Platform for RNA Delivery
Polypeptide Nanoparticle Platform for RNA Delivery Backbone PNP delivery platform is a potential game changer Significant advantages against existing platforms siRNA is much more than for hepatocytes of the liver ✓ A wide range of organs targeted: High delivery Validated safety High packaging Simple

Slide 13: GalAhead – Sirnaomics Proprietary GalNAc 2.0 Delivery
GalAhead™ – Sirnaomics Proprietary GalNAc 2.0 Delivery RNAi Trigger 1. Smallest RNAi Trigger 2. Easier CMC Process GalAhead™ 3. Good Safety Profile GalNAc 2.0 4. Long-Lasting Efficacy Linker 5. Strong IP Position ***************************************************************************** partnersh

Slide 14: GalAhead – Unique Design and Mechanism of Action
GalAhead™ – Unique Design and Mechanism of Action Conventional GalNAc-siRNA Structure GalAhead™ Delivery Platform GalAheadTM Key points: Key points: ◼ Two single strands ◼ 1 Hairpin structure ◼ 3 major synthesis steps; 42+ nucleotides ◼ 1 major synthesis step; 29-33 nucleotides 13

Slide 15: Clinical Achievements
° ° Advancing RNAi Therapeutics PEAS Clinical Achievements ele

Slide 16: Core Product: STP705
Core Product: STP705 (Local Formulation) A. NMSC - isSCC, BCC B. Fat Remodeling 15

Slide 17: Innovative Dual-Targeted RNAi Therapeutics
Innovative Dual-Targeted RNAi Therapeutics Targeting both TGF-ß 1 and COX-2 Selection of “Gate Keeper” Targets TGF-β1 COX-2 PGE2 TGF-βrII, TGF- βrI EP2 P Smad2 P Smad3 γ β 𝛼𝑠 PI3K -P Small independent pathways GSK- P P P P Axin AC Axin AKT 3β MAPK PI3K Smad2 Smad3 Smad2 Smad3 GSK3 Smad4 TIF1γ β-…

Slide 18: Non-Melanoma Skin Cancers (NMSC)
Non-Melanoma Skin Cancers(NMSC) One of the most common cancers in the U.S. with growing market potential Overview ◼ BCC and SCC account for the majority of NMSCs with more than five million Annual number newly diagnosed cases estimated to occur in the U.S. every year of deaths from 57% 42% ◼ Squamou

Slide 19: STP705 isSCC – Positive Phase IIa Results
STP705 isSCC – Positive Phase IIa Results Comparison between current treatment options Ph IIa Study design and results and STP705 treatment ◼ A total of up to 25 subjects ◼ Surgery, curettage and electrodesiccation are the cornerstone with diagonized isSCC, 5 treatments of NMSC. However, they have h

Slide 20: STP705 isSCC – Positive Phase IIb Results
STP705 isSCC – Positive Phase IIb Results Ph IIb study design and results ◼ The double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy, administered as an intralesional injection in subjects with isSCC ◼ The study investigated 32 patients with 30 µg/ml, 60 µg/ml and 9

Slide 21: STP705 BCC – Positive Phase II Results
STP705 BCC – Positive Phase II Results Ph II study design and results Cohort A: 30 μg Cohort B: 60 μg Cohort C: 90 μg Cohort D: 120 μg Cohort E: 180 μg Cohort F: 240 μg (N=5) (N=5) (N=5) (N=5) (N=5) (N=5) 1/5 3/5 3/5 2/5 5/5 3/5 Histological Clearance 20% 60% 60% 40% 100% 60% Average Skin Response S

Slide 22: STP705 isSCC – FDA Cleared for Late-Stage Study
STP705 isSCC – FDA Cleared for Late-Stage Study 10 centers 15 centers No. of subjects 25 No. of subjects 44 No. of subjects 200 No. of subjects 300 STP705 isSCC STP705 isSCC STP705 isSCC STP705 isSCC Phase IIa study Phase IIb study confirmatory study confirmatory study ◼ Well-positioned to advance S

Slide 23: STP705 Fat Remodeling – Target c.US$10b Global Market
STP705 Fat Remodeling – Target c.US$10b Global Market Global market increases from US$ 3.5b in 2022 to US$ 9.4b in 2030 Global market size of submental fat reduction treatment, 2022-2030 CAGR 2022-30E US$ billion Total 13.2% Market size of non-invasive submental fat reduction 17.8% 9.4 8.3 Market si

Slide 24: STP705 Fat Remodeling – Mechanism of Action
STP705 Fat Remodeling – Mechanism of Action TGF-β1 and Obesity COX-2 and Obesity ◼ Recent findings on the role of TGF-β1/Smad3 signaling in ◼ COX-2 is the key enzyme in eicosanoid metabolism that the pathogenesis of obesity and type 2 diabetes have converts eicosanoids into a number of PGs, includin

Slide 25: STP705 Fat Remodeling Vs Commercial Product X
STP705 Fat Remodeling Vs Commercial Product X STP705/Commercial Product X Comparison Study Preclinical Animal Model Study Results Product X Thickness of Adipose Tissue Control (µm) STP705 Treatment Study Design ◼ Animal Model:minipig, N = 3 ◼ Administration: Subcutaneous, Comparison ◼ Commercial pro

Slide 26: STP705 Fat Remodeling – Positive Phase I Interim Results
STP705 Fat Remodeling – Positive Phase I Interim Results Phase I clinical observation completed ◼ To evaluate the safety and tolerability of STP705, delivered via subcutaneous injection. STP705 was administered to 6 subjects on day 1, 28 and 56. Each subject will be treated with 7 injection points.

Slide 27: Lead Product: STP707
Lead Product: STP707 (Systemic Formulation) 26

Slide 28: STP707 Multiple Solid Tumor – Phase I Study Design
STP707 Multiple Solid Tumor – Phase I Study Design Phase I study design In November 2021, we initiated a Phase I clinical trial for solid tumors in the U.S. Solid tumors include Liver cancer, Pancreatic cancer, Colon cancer, Melanoma, etc. Completion of patient dosing: intravenous systemic administr

Slide 29: STP707 Multiple Solid Tumor – Exhibit Clinical Benefits
STP707 Multiple Solid Tumor – Exhibit Clinical Benefits Stable Disease 74% 74% of evaluable patients demonstrated a best response of SD & several patients exhibited reduction in tumor burden per Response Evaluation Criteria in Solid Tumors (RECiST) 28

Slide 30: STP707 Multiple Solid Tumor – Selected Study Results (1/2)
STP707 Multiple Solid Tumor – Selected Study Results (1/2) Patient 101-005 (6mg) Treatment Cancer Type: Pancreas Age: 65 Sex: Female Race: White Treatment Years of Treatment Duration (Days) Best Response Leucovorin Calcium Irinotecan Hydrochloride 2018 93 Unknown Fluorouracil Oxaliplatin Gemzar + Xe

Slide 31: STP707 Multiple Solid Tumor – Selected Study Results (2/2)
STP707 Multiple Solid Tumor – Selected Study Results (2/2) Patient 103-001 (6 mg) Treatments Cancer Type: Liver Age: 62 Sex: Male Race: White Treatment Years of Treatment Duration (Days) Best Response Leucovorin Calcium Fluorouracil 2018-2019 498 SD Oxaliplatin Avastin Leucovorin Calcium Fluorouraci

Slide 32: STP707 Multiple Solid Tumor – Results and Next Step
STP707 Multiple Solid Tumor – Results and Next Step Phase I primary results and next step Primary Results: ◼ No drug related AE and SAE were observed ◼ All dosages demonstrated very good safety profile ◼ “Stable Disease” are observed for a certain period of time ◼ Exploring potential Phase II combin

Slide 33: Lead Product: STP122G
Lead Product: STP122G (Subcutaneous Injection) Liver Targeting, Factor XI, Anticoagulant Drug 32

Slide 34: STP122G Anticoagulation – Functional Validation
STP122G Anticoagulation – Functional Validation 33

Slide 35: STP122G Anticoagulation – Phase I Study Design
STP122G Anticoagulation – Phase I Study Design First clinical asset developed on the GalAheadTM delivery platform Phase I study design ◼ Study Design: ◼ Single-center, randomized, double-blind, sequential cohort study is designed to evaluate the safety, tolerability, Pharmacokinetics and Pharmacodyn

Slide 36: STP122G Anticoagulation – Selection of Indications
STP122G Anticoagulation – Selection of Indications Occurrence rate Sample size for Observation Cost for Indication of venous Phase III study Period Phase III study thromboembolism (VTE) Total knee 30% to 70% 500 12 days to 1 month relatively low replacement Cancer with I/O 25% 600 to 800 1 to 3 mont

Slide 37: Future Milestones & Catalysts
Future Milestones & Catalysts 36

Slide 38: Milestones and Expected Catalyst events
Milestones and Expected Catalyst events Product Current Phase Key milestones Time Complete Phase IIb study Q1 2023 STP705 Phase IIb Obtained guidance from FDA for late-stage development Q2 2023 isSCC Start late-stage clinical study Q4 2023 Complete Phase II study Q3 2023 STP705 Phase II Obtained gui

Slide 39: Global Partnerships – Business Development Focus
Global Partnerships – Business Development Focus STP705 STP705 Fat NMSC Remodeling Maximize Pipeline Value and Future Potentials STP707 GalAheadTM Solid Tumor Programs Portfolio of preclinical and clinical assets ready for global partnership to unlock value of the dual delivery platforms 38

Slide 40: Group Strategy
Group Strategy Re-evaluation R&D Strengthen Focus on Value Creation Pipeline competitiveness Reassess and prioritize Pursue synergistic First-in-Class and Best- of our R&D pipeline collaboration in-Class delivery platforms and pipelines Reallocate resource Actively seek business Capabilities of in-h

Slide 41: Financial Highlights
° ° Advancing RNAi Therapeutics PEAS Financial Highlights ele

Slide 42: Statement of Profit and Loss
Statement of Profit and Loss For six months ended 1. Changes in Fair Value of Financial Assets and Liabilities at Jun 30 FVTPL: 2023 2022 ◼ Changes in fair value of financial liabilities at FVTPL balances in Ref US$ (m) US$ (m) 2022 (US$ 2.9m) and 2023 (US$0.5m) are for the FV loss (non- Revenue Nil

Slide 43: Cash Flow Statement
Cash Flow Statement For six months ended Jun 30 1. Net cash used in operating activities: Decreased from 2023 2022 US$45.4m to US$38.3m due to restructuring and Ref US$ (m) US$ (m) US$ (m) US$ (m) prioritization of pipelines development Cash and cash 105.2 212.0 equivalents on Jan 1 2. Net cash used

Slide 44: Advancing RNAi Therapeutics – Q&A
° ° Advancing RNAi Therapeutics Las) Q&A
Source: company website





